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The apparent rarity of pulmonary hyperten-
sion (PH) explains why interest in this disease has
long been moderate. It was only in 1973 that a
WHO symposium defined its clinical picture,
pathology, presumed pathogenesis, diagnosis and
treatment, and in 1998 that another WHO con-
ference defined risk factors (such as appetite-sup-
pressing drugs) and medical associations (genetic
factors, HIV infection, collagen vascular disease,
portal hypertension) which may cause PH [1].
Both improvement of echocardiography as a bed-
side diagnostic tool which has made estimation of
pulmonary artery pressure easy, repeatable and re-
liable [2], and the publication of favourable results
regarding exercise tolerance, haemodynamic vari-
ables and survival in patients treated with
prostanoids has renewed clinical interest in PH
[3–6]. It is in this context that the Swiss Registry
has been initiated to palliate the paucity of data and
probable biases relating to existing data, and to de-
fine prognostic parameters associated with life ex-
pectancy.
Background: Severe pulmonary hypertension
(PH) is a rare disease with a dismal prognosis if un-
treated. Progress in diagnosis and in the develop-
ment of effective therapeutic options has created
new interest in this pathology. There are, however,
only limited data on the prevalence of severe PH
unrelated to chronic left ventricular failure or
COPD, on the associated conditions and on the
parameters with a prognostic impact. With the aid
of a retrospective registry we have collected data
from 5 centres in Switzerland and attempted to an-
swer the above questions.
Methods: Data on patients with PH from 4 uni-
versity facilities (Zurich, Basle, Geneva and Lau-
sanne) and one well-defined geographical area (Ti-
cino) were retrospectively collected and analysed
up to December 1999. Clinical and haemodynamic
parameters and associated diseases were noted. We
were also interested in the age distribution of the
patients and the year of diagnosis of PH. 
Results: We found 106 patients with severe PH
(43 men, 63 women, median age 43 years); 79%
were in NYHA class III or IV. There was a steep
rise in diagnosis of PH after 1995. In 74% PH was
either primary or associated with collagen vascu-
lar disease or thromboembolic disease. By the end
of the observation period 30% of the patients had
died. The best distinguishing parameters between
surviving patients and those who eventually died
were the 6-minute walking test (363 vs. 235 me-
tres, p = 0.002), the NYHA class (II vs III/IV, p 
= 0.015), and mixed venous saturation (66.5 vs.
57.9%, p = 0.006). Therapy consisted of calcium
antagonists in 18% and of (inhaled) prostanoids,
chiefly iloprost, in 33%. Seven patients underwent
lung transplantation.
Conclusions: We conclude that PH is diagnosed
more often as diagnostic and therapeutic options
improve; that primary forms, and those associated
with collagen vascular disease and with chronic ve-
nous thromboembolism, make up three-quarters
of the aetiologies; and that the 6-minute walking
test, the functional class and mixed venous satura-
tion are the best prognostic parameters.
Keywords: pulmonary hypertension; registry; aeti-
ology; prognosis
Summary
Introduction
346Original article S W I S S  M E D  W K LY 2 0 0 1 ; 1 3 1 : 3 4 6 – 3 5 0 ·  w w w. s m w. c h
Peer reviewed article
S W I S S  M E D  W K LY 2 0 0 1 ; 1 3 1 : 3 4 6 – 3 5 0 ·  w w w. s m w. c h 347
Data were collected retrospectively from 4 Swiss uni-
versity centres and Ticino (an area with a well-defined
population from the southern part of Switzerland). A small
proportion of the data were communicated by individual
specialists after a call for patients had been published in
the Swiss Medical Bulletin in 1999; these data were re-
viewed by one of us (GD). The data collected were stud-
ied in order to form a picture of the frequency of diagno-
sis as a function of time and the patients’ age at the mo-
ment of diagnosis; to assess the conditions associated with
PH; to establish a relation between clinical parameters and
survival; and to assess the patients’ treatment.
PH was defined as mean pulmonary artery pressure
>25 mmHg at rest [7]. Secondary causes of PH (not con-
sidered in the registry), such as left heart disease with in-
creased pulmonary wedge pressure and obstructive lung
disease, were ruled out by cardiac catheterisation and lung
function tests. Associated causes of precapillary pul-
monary hypertension were assessed by appropriate means
(serological testing for connective tissue diseases and HIV
infection, history and imaging for portal hypertension,
history for anorectic agents, and cardiac catheterisation
for Eisenmenger’s syndrome). 
Clinical and haemodynamic parameters included
NYHA class, 6-minute walking test, cardiac index (CI),
mean pulmonary wedge pressure (PWP), systolic (PAP-
syst) and mean (PAPmean) pulmonary artery pressure,
pulmonary vascular resistance (PVR), mixed venous oxy-
gen saturation (SvO2), partial arterial oxygen pressure
(PaO2 ) and arterial oxygen saturation (SaO2).
The statistical significance (p <0.05) of the parame-
ters between deceased and surviving patients was assessed
by two-tailed t-test. The difference in NYHA functional
class between these two patient groups was calculated by
Fisher’s exact test. 
Material and methods
Results
In the period to end-1999 106 patients were
retrieved (43 men and 63 women). 10% of patients
had a diagnosis of PH before 1990; 4 patients (all
surviving) originated from the anorexigen epi-
demics in the 1960s [8]. Age distribution is shown
in figure 1; there is a preponderance of younger pa-
tients diagnosed with PH, 63 (59%) being under
50 at the time of diagnosis; the median age was 43.
Only 14 out of the 106 patients had been diagnosed
before 1990, and we observed a steep rise in the
number of cases after 1995 (fig. 2). Table 1 shows
the aetiological distribution of PH, with primary
PH, PH associated with collagen vascular disease,
and chronic thromboembolic PH representing
74% of our patient sample. 
In 17 of our patients (16%) parameters of right
heart catheterisation were lacking. These patients
were nonetheless included when the history was
consistent with the diagnosis of PH. One patient
with collagen vascular disease had died, 15 were
alive (3 with primary PH, 1 with thromboembolic
PH, 4 with a history of anorexic medication, 3 with
collagen vascular disease, and 4 with HIV infec-
tion).
Clinically, most patients (79%) were in NYHA
class III or IV. 32 (30%) patients had died by the
end of 1999. The data of patients with available
haemodynamic assessment are shown in Table 2,
with a comparison of the parameters in surviving
and dead patients. The 6-minute walking test (363
± 135 in surviving patients vs. 235 ± 155m in pa-
tients who did not survive; p = 0.002), mixed ve-
nous oxygen saturation (66.5 ± 9.5 vs. 57.9 ±
10.1%, p = 0.006) and NYHA functional class (2
patients in class II and 30 in class III/IV for patients
who did not survive vs 18 in class II and 44 in class
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Figure 1
Age distribution in
patients with PH.
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III/IV for surviving patients, p = 0.015) best dis-
tinguished the two groups, whereas mean or sys-
tolic pulmonary artery pressure differed less sig-
nificantly (p = 0.06 and 0.05 respectively); pul-
monary vascular resistance did not differ between
the two groups.
Nearly two-thirds of the patients (67 out of
106) were anticoagulated, whereas only 19 (18%)
were given a calcium antagonist; 6 of these 19 pa-
tients (31%) had died (2 of the 6 also inhaled
prostacyclin). 35 patients (33%) inhaled epopros-
tenol or a more stable analogue, iloprost; one of
them was later switched to intravenous iloprost
because of aggravation of the disease. There were
no other patients on intravenous prostacyclin. 
26 of the patients under prostanoids (74%) were
alive and 9 (26%) had died. 
Seven patients underwent lung transplanta-
tion (4 with thromboembolic disease, 2 with pri-
mary disease and 1 with Eisenmenger’s syndrome),
5 of whom are still alive.
A similar number of patients among survivors
and those who eventually died were treated with
prostanoids or lung transplantation. 
UK (%) CH (%)
Primary PH 33 37
Venous thromboembolism 13 15
Collagen vascular disease 20 22
Hypoxaemia 4 –
Congenital heart disease 30 4
HIV/anorexic agents/ – 22
portal hypertension
Table 1
Aetiological distribu-
tion in patients with
pulmonary hyperten-
sion (PH). Compari-
son between data of
United Kingdom (UK)
and Switzerland (CH).
N surviving dead p
(× ± SD) (× ± SD)
6´ walk test (m) 62 363 ± 135 235 ± 155 0.002
SvO2 (%) 66 66.5 ± 9.5 57.9 ± 10.1 0.006
PAPm (mm Hg) 82 53 ± 12 59 ± 13 0.06
PAPs (mm Hg) 82 81 ± 19 84 ± 21 0.05
PVR (dyn.sec.cm-5) 67 892 ± 419 959 ± 455 0.11
PaO2 (kPa) 72 9.1 ± 1.8 9.2 ± 2.3 0.9
NYHA class II vs III/IV (n) 94 18 vs 44 2 vs 18 0.015
Table 2
Comparative parame-
ters between dead
and surviving pa-
tients with PH. 
SvO2 = mixed venous
oxygen saturation,
PAPm = mean pul-
monary artery pres-
sure, PAPs = systolic
pulmonary artery
pressure, PVR = pul-
monary vascular
resistance, N = num-
ber of patients tested. 
Figure 2
Number of patients
diagnosed with PH.
Discussion
A classical approach to gaining insight into
rare diseases is to establish a registry, which ideally
should be based on prospective collection of data
according to a standardized protocol [9]. But even
a well-designed data collection protocol has its
shortcomings: the true incidence of PH may be un-
derestimated even in prospective studies. Data col-
lection centres depend on contributing primary
health care providers and primary/secondary facil-
ities, and less awareness of a disease means less re-
ferral of patients to tertiary hospitals. This mech-
anism may account for the fact that the so far
largest prospective data collection on PH from the
prospective national registry in the USA, with 32
participating centres, yielded relatively few pri-
mary PH patients (n = 194) over 4.5 years (1981 to
1985), compared to our 31 patients diagnosed with
primary PH within 5 years (1995 to 1999) [10]. A
recent publication presented data collected on the
basis of death registries; a temporal rise in mortal-
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ity was found, which could equally well have been
due to better diagnosis as to a real increase in the
disease [11]. New registry-based data on PH are,
however, lacking.
In recent years the well-established therapy of
intravenous prostacyclin for primary pulmonary
hypertension [12] has been extended successfully
to patients with PH associated with collagen vas-
cular disease [13], HIV infection [14], portal hy-
pertension [15], chronic venous thromboem-
bolism [4] and pulmonary hypertension secondary
to congenital heart defects [16]; we therefore in-
cluded patients with other than primary PH in our
registry, in line with a suggestion of Voelkel [17].
The present registry is therefore not directly com-
parable with former ones which included only pa-
tients with primary PH [10]. To our knowledge
this is the first registry to enroll patients with se-
vere PH of various aetiologies which eventually re-
sult in a common final clinical pathway, i.e. right
heart failure.
Our findings show that in 74% of cases pul-
monary hypertension unrelated to left heart fail-
ure or obstructive lung disease was caused by 3
pathological conditions: the primary form, PH as-
sociated with collagen vascular disease, and PH
caused by chronic thromboembolic disease. 
We confirm a relatively young age at the time
of diagnosis (median 43 years), though one that is
higher than in other studies [18]; this impression
is shared by Lilienfeld and Rubin, whose results
suggested that the disease may be more common
in the elderly [11]. Older age groups are probably
underrepresented in earlier studies: in a data col-
lection published in 1979 the age distribution in
patients with primary PH showed a peak incidence
between ages 25 and 29, and there were no patients
over 60 [19]. One possible explanation is that the
unspecific symptoms of PH, such as dyspnea, are
falsely attributed to left heart failure, a condition
frequently encountered in elderly people. Women
were affected more often than men (female to male
ratio 1:4, which is slightly lower than the reported
ratio of 1:7–3:5). At the time of diagnosis most pa-
tients (79%) already presented advanced func-
tional impairment (NYHA class III/IV), which
again can be explained by the insidious onset of the
disease and the resultant pre-diagnosis delay dur-
ing which it is unsuspected. Our data show a steep
rise in the number of cases diagnosed between
1996 and 1999 compared to those registered be-
tween 1991 and 1995. This finding is probably as-
cribable to better diagnostic tools and not to a
higher incidence of the disease, although it is not
possible to draw definite conclusions from our se-
ries.
Among the prognostic parameters for survival
we found that the 6-minute walking distance,
NYHA functional class and mixed venous oxygen
saturation distinguished surviving patients from
those who would have died better than strictly
haemodynamic data such as pulmonary artery
pressure or resistance. With the walk test in par-
ticular the clinician has a very simple tool for strat-
ifying patients into a high- and a low-risk group.
The usefulness of these two parameters has already
been mentioned [3, 4]. 
Classical therapy with vasodilators, digitalis,
diuretics, anticoagulants, or oxygen did not alter
survival in the study of D’Alonzo [10]. Among our
patients relatively few (18%) were given a calcium
antagonist, well below the number in the above-
cited study where more than 80% received a va-
sodilator; this may be partly due to our more re-
cent period of data collection, where prostanoid
therapy had already been implemented, and reflect
the fact that 25% at most of the patients improved
under calcium antagonists [20]. Our data, however,
are not suitable for drawing conclusions regarding
the new vasodilator therapy’s positive effects on
survival.
Our collection of data on PH has the short-
coming of being retrospective, which may involve
inconsistency of data and missing parameters.
However, we feel that the present study is repre-
sentative since it compares well with a British study
on the distribution of primary PH and PH associ-
ated with other diseases (T. Higenbottam, per-
sonal communication); moreover, the present data
allowed us to define clinical and haemodynamic
parameters which correlated with mortality. 
From our retrospectively-collected data on
patients with severe PH from 5 centres in Switzer-
land we conclude that the disease has been more
frequently diagnosed in recent years; that the age
spectrum of the patients is changing, with a ten-
dency for more elderly people to be diagnosed with
PH; and that the easily obtainable 6-minute walk-
ing distance, NYHA functional class and mixed ve-
nous oxygen saturation are better prognostic pa-
rameters than pulmonary artery pressure values. 
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